The novel antibody therapies market for advanced stage drugs is anticipated to grow at a CAGR of 36% by 2035
Written by james hebrewOwing to the recent approval of therapies, such as Elzonris®, Pluvicto®, there has been a substantial increase in the R&D activity to evaluate the use of novel ..